Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of Deucravacitinib BMS-986165 in adolescents aged 12 to 17 years with moderate to severe plaque psoriasis. The study aims to assess the drugs effectiveness, safety, and how it behaves in the body. This phase 3 trial is designed as a randomized, double-blind, placebo-controlled investigation to provide clear evidence of the drugs impact in this younger population. Participants are randomly assigned to receive either Deucravacitinib or a placebo following specified dosing schedules. The study involves a parallel group design where the treatment is given on specified days. The trial will monitor participants closely over time to evaluate treatment responses and any side effects, especially focusing on improvements in psoriasis severity and skin condition. During the study, participants will have regular assessments including measurement of psoriasis severity by Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA, body surface area affected, itch severity, and quality of life. Safety monitoring includes checking for adverse events, laboratory tests, physical exams, vital signs, and vaccine antibody levels. The study also tracks growth and sexual maturation over up to five years, providing long-term data on drug safety and participant health.
Actively Recruiting
Researchers are studying if the drugs abemaciclib and letrozole are effective and safe for people with advanced or recurrent estrogen receptor positive ER, mismatch repair proficient, TP53 wild-type endometrial cancer. This phase 2 trial specifically looks at maintenance treatment after initial chemotherapy with carboplatin and paclitaxel, with or without anti-PD-L1 therapy. The FDA has not approved these drugs for endometrial cancer, but they are approved for other uses. Participants will receive oral abemaciclib twice daily and letrozole once daily in 21-day cycles for up to 2 years. The treatment schedule involves continuous dosing with scans X-ray, CT, MRI, or PET every 9 weeks for the first 9 months, then annually. The study includes a baseline scan, regular treatment cycles, an end-of-treatment visit with assessments and scans, followed by a 3-year follow-up period. During the study, participants will have various scans and blood tests to monitor their cancer status and overall health. Electrocardiograms EKGs will also be conducted. Researchers will measure progression-free survival over up to 2 years as the main outcome, along with adverse event rates, overall survival up to 5 years, and response rates. Participants adherence to oral medication will be monitored, and safety will be followed closely throughout treatment and the extended follow-up period.
Actively Recruiting
Researchers are evaluating a new imaging approach for men with intermediate- or high-risk prostate cancer who plan to receive hormone therapy and radiation treatment. The study aims to see if using a special imaging test during hormone therapy can help doctors better identify where active cancer remains in the prostate. This could allow for more precise radiation targeting, potentially reducing side effects by avoiding unnecessary treatment to healthy areas. All participants will receive standard hormone therapy androgen deprivation therapy or ADT for about six months, combined with stereotactic body radiation therapy SBRT beginning around 10 weeks after starting ADT. Three PSMA PETCT scans and MRI scans will be performed before hormone therapy begins, about eight weeks after ADT starts before radiation planning, and at 24 weeks end of treatment. Based on these scans, some patients may receive an extra focused radiation boost to areas where active cancer remains, while others may not need this boost if the cancer has responded well. Participants will be monitored with imaging, blood tests measuring PSA levels, and patient-reported quality of life questionnaires focusing on urinary, bowel, and sexual symptoms. Researchers will assess how well the imaging guides radiation planning and treatment targeting. The total participation lasts about six months, during which standard treatments are combined with experimental imaging to improve radiation precision and reduce side effects for future patients.
Actively Recruiting
Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.
Actively Recruiting
Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.
Actively Recruiting
This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are studying glioblastoma GBM, a fast-growing brain cancer affecting older adults who have special medical and care needs. This trial explores whether giving higher radiation doses in fewer sessions dose-escalated hypofractionation can improve treatment outcomes compared to the standard shorter radiation course. The study is a phase 2 randomized trial aiming to compare safety and effectiveness of these two radiation schedules in people aged 65 and older with newly diagnosed GBM. Participants will receive radiation therapy for three weeks, either as a standard hypofractionated regimen or a dose-escalated hypofractionated regimen with higher daily radiation doses. Both approaches deliver fewer radiation treatments than traditional schedules but differ in daily dose intensity. The study randomly assigns patients to one of these two groups to assess which approach may offer better results. During the trial, participants undergo screening to confirm eligibility, receive radiation treatments, and have follow-up visits to track symptoms and side effects. Researchers will measure overall survival, progression-free survival, treatment-related side effects, quality of life, mood, geriatric assessments, and performance status over up to six months after enrollment. The study will monitor participants for about one year on average to evaluate the effects of the treatments.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.
Actively Recruiting
Researchers are comparing two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, both with or without the immunotherapy drug nivolumab, for treating patients with advanced, unresectable, or metastatic HER2-negative adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. This phase III trial aims to see if mFOLFIRINOX with or without nivolumab improves overall survival compared to mFOLFOX with or without nivolumab. The study also evaluates treatment safety, response rates, and explores biomarkers like PD-L1 combined positive score and cell-free DNA. Participants randomized to one of two groups will receive intravenous chemotherapy every 14 days in cycles up to 12 times. One group receives fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan, with nivolumab given as clinically indicated. The other group receives fluorouracil, leucovorin calcium, and oxaliplatin, also with nivolumab as needed. Throughout the study, patients undergo MRI and CT scans and may have blood samples collected. Nivolumab administration depends on clinical need. During the trial, participants will have regular imaging to monitor tumor status and blood tests to track biomarkers. Patient-reported outcomes on treatment side effects are collected at baseline and during cycles. After treatment, participants are followed every six months for up to three years or until tumor progression or withdrawal. The main outcome measured is overall survival over two years, with additional assessments of progression-free survival, response duration, and safety up to three years.
1-10 of 23
1